1. Inicio
  2. Proyectos y Estudios
  3. A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by openlabel extension in participants with early Alzheimer’s disease.

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by openlabel extension in participants with early Alzheimer’s disease.

Datos básicos

ENSAYO CLÍNICO ACT23645 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2026

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT

Cita

Compartir